Hello Bio, Inc.
304 Wall St., Princeton, NJ 08540 USA

T. 609-683-7500
F. 609-228-4994

customercare-usa@m2stage.hellobio.com

DATASHEET

YM 298198 hydrochloride

Product overview

Name	YM 298198 hydrochloride
Cat No	HB0664
Alternative names	YM 298198
Biological action	Antagonist
Purity	>99%
Description	Potent, selective, non-competitive $mGlu_1$ antagonist

Images

Biological Data

Biological description	Potent, selective and non-competitive $mGlu_1$ receptor antagonist (IC_{50} = 16 nM). Shows antiproliferative effects in cancers expressing $mGlu_1$ receptor.

Solubility & Handling

Storage instructions	+4°C (desiccate)
Solubility overview	Soluble in water (100mM)
Important	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Chemical Data

Chemical name	6-Amino-*N*-cyclohexyl-N,3-dimethylthiazolo[3,2-*a*]benzimidazole-2-carboxamide hydrochloride
Molecular Weight	378.92
Chemical structure	
Molecular Formula	$C_{18}H_{22}N_4OS.HCl$
CAS Number	748758-45-4
PubChem identifier	45073464
SMILES	CC1=C(SC2=NC3=C(N12)C=C(C=C3)N)C(=O)N(C)C4CCCCC4.Cl
InChi	InChI=1S/C18H22N4OS.ClH/c1-11-16(17(23)21(2)13-6-4-3-5-7-13)24-18-20-14-9-8-12(19)10-15(14

Chemical name	6-Amino-*N*-cyclohexyl-N,3-dimethylthiazolo[3,2-*a*]benzimidazole-2-carboxamide hydrochloride
	)22(11)18;/h8-10,13H,3-7,19H2,1-2H3;1H
InChiKey	WYTJVUVCSUWZTH-UHFFFAOYSA-N
MDL number	MFCD08703122

References

Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor ty

Kohara A *et al* (2005) J Pharmacol Exp Ther 315(1)
PubMedID 15976016

Potent and specific action of the mGlu1 antagonists YM-298198 and JNJ16259685 on synaptic transmission in rat cerebellar slices.

Fukunaga I *et al* (2007) Br J Pharmacol 151(6)
PubMedID 17502847

Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer.

Speyer CL *et al* (2014) PLoS One 9(3)
PubMedID 24633367